Armata Pharmaceuticals, Inc.
ARMP · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $2 | $0 | $1 |
| % Growth | -46.6% | 341.8% | -60.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $2 | $0 | $1 |
| % Margin | 68.1% | 83.1% | 23.2% | 69.2% |
| R&D Expenses | $6 | $6 | $5 | $8 |
| G&A Expenses | $0 | $3 | $3 | $3 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | -$0 |
| Operating Expenses | $9 | $9 | $8 | $11 |
| Operating Income | -$8 | -$7 | -$8 | -$11 |
| % Margin | -670.9% | -315.5% | -1,668.2% | -853.4% |
| Other Income/Exp. Net | -$19 | -$9 | $2 | $13 |
| Pre-Tax Income | -$27 | -$16 | -$7 | $3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$27 | -$16 | -$7 | $3 |
| % Margin | -2,301.6% | -751.3% | -1,330.1% | 210.5% |
| EPS | -0.74 | -0.45 | -0.18 | 0.072 |
| % Growth | -64.4% | -150% | -350.3% | – |
| EPS Diluted | -0.74 | -0.45 | -0.18 | 0.044 |
| Weighted Avg Shares Out | 36 | 36 | 36 | 36 |
| Weighted Avg Shares Out Dil | 36 | 36 | 36 | 59 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $4 | $4 | $4 | $3 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$22 | -$12 | -$3 | $6 |
| % Margin | -1,894.7% | -558.8% | -519.8% | 506.9% |